Telomir Pharmaceuticals, Inc.

TELOdata completeness 50%4 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'capex'; no data for concept 'cash'; no data for concept 'totalDebt'; no data for concept 'incomeTaxExpense'; no data for concept 'pretaxIncome'

The thesis, from the filings

Telomir Pharmaceuticals, Inc. earns about -1042% on equity, but has diluted owners by 18% over 4 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own

Figure	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	—	—	—	—
Net income	−$854,147¹	−$13.1M²	−$16.5M³	−$10.4M³
Operating cash flow	−$468,661⁴	−$3.86M⁵	−$5.07M⁶	−$3.69M⁶
Capital expenditure	—	—	—	—
Free cash flow (derived)	—	—	—	—
Total debt	—	—	—	—
Cash & equivalents	—	—	—	—
Diluted shares	26.8M	27.3M	29.5M	31.7M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

$1.87

your share of equity

Profit it earned you last year

−$3.29

Free cash flow it threw off

—

Debt you’d be carrying

—

10 shares is a claim on $1.87 of net worth that earned you −$3.29 last year.

iii. Is this a good business?

Moat signal · return on equity

-1042% avg · 4y

FY22 —FY23 -380%FY24 -2571%FY25 -176%

It earned an average -1042% on equity over 4 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →

Management signal · capital allocation

+18% shares · 4y

Share count is up 18% over 4 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts

10-K · period ending 2022-12-31 · accession 0001493152-24-012049 (NetIncomeLoss)
10-K · period ending 2023-12-31 · accession 0001493152-25-004872 (NetIncomeLoss)
10-K · period ending 2024-12-31 · accession 0001493152-26-010625 (NetIncomeLoss)
10-K · period ending 2022-12-31 · accession 0001493152-24-012049 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2023-12-31 · accession 0001493152-25-004872 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2024-12-31 · accession 0001493152-26-010625 (NetCashProvidedByUsedInOperatingActivities)